ArticleBMC cancer2026
ZCCHC4 drives glioma progression and serves as a prognostic biomarker.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGliomas are the most prevalent and aggressive primary tumors of the central nervous system, with glioblastoma (GBM) exhibiting rapid progression, high recurrence, and poor prognosis. Therapeutic resistance, particularly to radiotherapy and chemotherapy, remains a major clinical challenge. RNA-binding proteins and RNA methyltransferases have emerged as regulators of tumor progression and immune modulation. ZCCHC4, a zinc finger CCHC domain-containing RNA methyltransferase, has been implicated in cancer, but its biological role and mechanisms in glioma remain largely unexplored.
methodsGene expression profiles and clinical data from TCGA and CGGA databases were analyzed to assess ZCCHC4 expression and its correlation with clinicopathological features and patient prognosis. Immunohistochemistry, qRT-PCR, and western blotting were performed to evaluate ZCCHC4 expression in glioma tissues and cell lines. Functional assays, including CCK-8, colony formation, wound healing, and transwell migration assays, were conducted to investigate the effects of ZCCHC4 knockdown in vitro. In vivo xenograft models were used to assess tumor growth. RNA sequencing and pathway analyses (GO/KEGG/GSEA) were applied to explore transcriptomic changes, and ssGSEA was used to infer immune-associated signatures.
resultsZCCHC4 expression was elevated in glioma tissues and cell lines and was associated with higher WHO grade, IDH wild-type status, and unfavorable survival. ZCCHC4 knockdown suppressed glioma cell proliferation and motility in vitro and reduced xenograft growth in vivo. Transcriptomic profiling indicated that ZCCHC4 depletion was accompanied by downregulation of DNA replication/cell-cycle–related programs and upregulation of ER-stress/unfolded protein response–related signatures. ssGSEA-based immune deconvolution suggested that higher ZCCHC4 expression was associated with increased inferred Th2-related and macrophage signatures and decreased inferred cytotoxic T-cell and NK-cell signatures.
conclusionZCCHC4 is upregulated in glioma and associated with adverse clinicopathological features and survival. ZCCHC4 depletion attenuated proliferative and motility-related phenotypes in vitro and reduced xenograft growth in vivo, while transcriptomic analyses suggested links to DNA replication/cell-cycle and ER-stress/UPR programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.